The study of "budget impact" of antiglaucoma medicines, recommended for inclusion in formulary and insurance lists

Abstract

As a pathology that requires lifelong treatment, primary open-angle glaucoma (POAG) causes significant increase in direct (pharmacotherapy) and indirect costs (associated with partial or complete disability of patients with POAG). The work presents the results of pharmacoeconomic "budget impact" analysis of antiglaucoma medicines (AGMs), recommended for inclusion in the formulary (FL) and insurance (IL) lists of pharmaceutical servicing patients with POAG on the basis of results obtained from previous studies. The "budget impact" analysis is an important part of integrated pharmacoeconomic evaluation of the health care system with the results needed by public funding bodies, namely for compensation of costs for pharmacotherapy to patients and approval of documents for refunding. The results of pharmacoeconomic study of POAG treatment with medications, recommended for inclusion in FL and IL, allowed to indicate the POAG treatment regimens, which help not only save costs in context of perspective of budget impact, but also provide significant advantage in achievement of target intraocular pressure (IOP) (characterized by the lowest "cost-efficacy" rate); POAG pharmacotherapy regimens is considered cost-effective, which, requiring additional costs nevertheless provides greater efficacy in lowering IOP; dominant schemes, switching to which requires additional costs.